Targeted Genetics Corporation Updates Investors on Annual Meeting Matters

SEATTLE--(BUSINESS WIRE)-- Targeted Genetics Corporation (Pink Sheets:TGEN), or the Company, today announced that the Superior Court of the State of Washington issued an order authorizing the Company to set the record date for the Company’s next Annual Meeting on a date consistent with the Company’s bylaws and Washington law. This ruling follows the Company’s request that the Court reconsider its prior order resetting the record date for the Company’s next Annual Meeting from December 10, 2010 to December 2, 2010.

In accordance with the Court’s order, the Company’s bylaws, and applicable Washington law, the Company has fixed the close of business on January 19, 2011 as the record date for the Company’s next Annual Meeting, and has rescheduled the date of the Annual Meeting from January 27, 2011 to February 18, 2011, in order to comply with certain timing requirements of the Company’s bylaws.

Notes to Editors

About Targeted Genetics Corporation

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com.



CONTACT:

Targeted Genetics Corporation
David Poston, CFO & Company Secretary
+1 (206) 623-7612

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.